Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
about
Tumor-intrinsic oncogene pathways mediating immune avoidanceBreast cancer survival among young women: a review of the role of modifiable lifestyle factorsThe fate of chemoresistance in triple negative breast cancer (TNBC)Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.Cdc20 and securin overexpression predict short-term breast cancer survival.Neogenin expression is inversely associated with breast cancer grade in ex vivo.Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer.Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.Positive correlation between expression level of mitochondrial serine hydroxymethyltransferase and breast cancer grade.Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesALK alteration is a frequent event in aggressive breast cancers.DGCA: A comprehensive R package for Differential Gene Correlation Analysis.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cellsThe critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Harnessing the immune system for the treatment of breast cancer.Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.Radiotherapy and immune checkpoint blockades: a snapshot in 2016.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.Immunotherapy for the treatment of breast cancer.Role of inflammatory infiltrates in triple negative breast cancer.Therapies for triple negative breast cancer.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.CD73-adenosine: a next-generation target in immuno-oncology.Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.Advancing Immunotherapy in Metastatic Breast Cancer.Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.A new paradigm for tumor immune escape: β-catenin-driven immune exclusionLoss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer.Increased Tumour Infiltration of CD4+ and CD8+ T-Lymphocytes in Patients with Triple Negative Breast Cancer Suggests Susceptibility to Immune TherapySensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
P2860
Q26747707-D3C85DAC-6FFB-493F-B33A-8758E081185DQ26766205-F064FE56-20C9-424B-A72D-24169B0CF84AQ26775232-0A88955F-C76D-445A-B167-DC2039DB8DA6Q27311085-91FD4B78-604C-4CE1-86FD-34F05EF0EAF1Q28077815-81F4FEB4-3D12-489B-AD54-39FFAC8F8A1FQ30245184-1333F96E-B912-472E-9E01-FB5AF70BCBDAQ33584033-625126DB-8EBD-4942-97E3-D1A417A680B4Q33750165-F751DDB8-754C-4F84-82B0-680ED9612860Q34636370-0B847583-07B3-42B7-BB11-E3A96BF72542Q35009369-1B8B41F4-042D-4D1F-84AD-21116B40763AQ35185688-AA8C778F-B11C-4FB1-BA19-7958E7B530F2Q35624231-122B66BD-5DCE-4C5E-86C6-8AB6C50479C3Q35958861-AC582704-6203-44BB-895B-0AE28B6873ABQ36105958-EC7F16DD-05A1-43F2-A40F-EB4FC72895A8Q36193416-7402DDF9-B572-4B8E-B052-1E01079F00E7Q36854062-BE570697-69A3-4581-B33B-448FE2ACDAE1Q37236747-0DA0450C-B05A-4CD4-B6CE-B30B40750C25Q37413162-F88A8E3D-A2A9-4069-825F-914FE9EA6503Q37476039-0CCE3055-4034-49BE-81AA-0AFD86F4875FQ37525422-04897F5C-BF53-433F-A024-86C129388221Q37551762-6F881595-ADCF-4385-8479-EFB5A6186506Q37650735-C6D8FD0C-2A86-4BFB-877D-23E16BA83BA8Q38209586-E445DD31-413C-467D-A06E-CAC1C592D844Q38353772-4201971F-2E23-4D9F-9E8F-41068181B2DDQ38370266-DCD07C16-53F0-47B0-8FED-80F8EAADF3A2Q38424397-3360F128-50D2-4D55-BF9C-CF50AC4003A9Q38647802-F03735B2-95A3-4F28-A1D1-64C9E31E1633Q38707904-873C023B-8B93-4A0D-984D-7B5D68FA2A16Q38711094-AFD79ABC-F7F4-4ECA-A1B2-2C316969812DQ38944865-D2619F94-4F04-4685-B818-E4DD1B040CCCQ39096364-79E3425D-1183-42C5-BA4A-38F4D568AF9FQ39324161-5C80AC21-E2F4-415E-B8CB-AE844DD297F4Q40931689-B9959F8E-B856-4C6C-AAA9-DFED79EA2A07Q41489984-07646FED-7D43-40D6-98F5-0900B7FCC499Q41719270-DBE9A4E3-E5B2-4EE5-A957-CA90C561E919Q41836927-E532D110-5675-4BB4-BD04-A49EF724F120Q42442829-AE6A4650-6136-449B-B380-E6C624C2BCD5Q42516683-547D268D-F6FA-4A11-8D8B-B898BAD97AB3Q42672834-630ADE99-9620-4E39-9698-369FF8787F81Q42700740-8B27015D-CF7D-4D1D-8B63-AB37EC6914DF
P2860
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Immunotherapeutic approaches i ...... esearch and clinical prospects
@ast
Immunotherapeutic approaches i ...... esearch and clinical prospects
@en
type
label
Immunotherapeutic approaches i ...... esearch and clinical prospects
@ast
Immunotherapeutic approaches i ...... esearch and clinical prospects
@en
prefLabel
Immunotherapeutic approaches i ...... esearch and clinical prospects
@ast
Immunotherapeutic approaches i ...... esearch and clinical prospects
@en
P2860
P356
P1476
Immunotherapeutic approaches i ...... esearch and clinical prospects
@en
P2093
Bertrand Allard
John Stagg
P2860
P304
P356
10.1177/1758834012475152
P577
2013-05-01T00:00:00Z